WuXi PharmaTech Appoints Dr. Hui Cai as Vice President of Business Development

SHANGHAI, Oct. 22 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Hui Cai has been appointed as Vice President of Business Development. She will report directly to Dr. Richard M. Soll, Senior Vice President of Integrated Services.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Dr. Hui Cai was President of Inflexion BioPartners and Vice President of Corporate Development at HUYA Bioscience. Previously, Dr. Cai spent ten years at Johnson & Johnson Pharmaceutical Research and Development on multiple small molecule drug discovery programs, and is co- author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai was appointed by the Mayor of San Diego in 2002 as a Commissioner at City of San Diego Science and Technology Commission. She is Chair of the San Diego section of the American Chemical Society, and Chair of Board at SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association). Dr. Cai received her B.S. and M.S. in Chemistry from Peking University, Ph.D. from The Scripps Research Institute, and M.B.A. from UCSD Rady School of Management as a recipient of the distinguished DLA Piper - Athena FlexMBA Scholarship.

"I am very pleased to welcome Hui on board as we continue to enhance our business development," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Hui brings us a broad portfolio of expertise and experience in strategic planning, business development, and portfolio management, with which we are confident that our discovery business will grow rapidly."

SOURCE WuXi PharmaTech (Cayman) Inc.